The published literature suggests that malignant peripheral nerve sheath tumors (MPNST) occur at increased frequency in neurofibromatosis type 2 (NF2). A recent review based on incidence data in North America showed that 1 per 1000 cerebellopontine angle nerve sheath tumors were malignant. OBJECTIVE: To determine whether MPNST occurred spontaneously in NF2 by reviewing our NF2 database.
BACKGROUND:
The published literature suggests that malignant peripheral nerve sheath tumors (MPNST) occur at increased frequency in neurofibromatosis type 2 (NF2). A recent review based on incidence data in North America showed that 1 per 1000 cerebellopontine angle nerve sheath tumors were malignant. OBJECTIVE: To determine whether MPNST occurred spontaneously in NF2 by reviewing our NF2 database.
METHODS:
The prospective database consists of 1253 patients with NF2. One thousand and nine are known to be alive at last follow-up. The presence and laterality/pathology of vestibular schwannoma at diagnosis and last follow-up was sought. RESULTS: There were no cases of spontaneous MPNST with 2114 proven (n = 1150) and presumed benign (n = 964) vestibular schwannomas found. Two patients had developed MPNST (1 presumed) after having previously undergone stereotactic radiosurgery for a vestibular schwannoma. CONCLUSION: In this series, and from the literature, malignant transformation of a vestibular schwannoma was not a feature of NF2 in the unirradiated patient. NF2 patients should not be told that they have an increased risk of malignant change in a vestibular schwannoma unless they undergo radiation treatment. However, very much larger datasets are required before it can be determined whether there is any association between NF2 and MPNST in the unirradiated patient. www.neurosurgery-online.com N eurofibromatosis type 2 (NF2) is an autosomal dominant inherited condition characterized by the development of bilateral vestibular schwannomas (VS), but also a variety of other tumors both in the central and peripheral nervous system. This includes other cranial, spinal, peripheral nerve and intradermal schwannomas, cranial and spinal meningiomas, and intrinsic tumors of the spine and brain stem, which are predominantly ependymomas. These tumors are categorized in the Manchester criteria 1 (Table) . Two recent reviews have highlighted a potential increased risk of spontaneous malignant peripheral nerve ABBREVIATIONS: CNS, central nervous system; MPNST, malignant peripheral nerve sheath tumors; NF1, neurofibromatosis type 1; NF2, neurofibromatosis type 2; VSs, vestibular schwannomas sheath tumors (MPNST) in NF2. 2, 3 We have interrogated the Manchester NF2 database of 1253 NF2 patients for the presence of histologically proven MPNST and reviewed the literature.
METHODS
A review was undertaken of the NF2 database available to the senior author (DGE), which has ethical approval from blinded Research Ethics Committee (reference 10/H1008/74). The purpose was to identify cases of MPNST especially in relation to the eighth cranial nerve. The NF2 database consists of 1253 patients. Patients who fulfill at least Manchester criteria for NF2 or who have a proven pathogenic mutation in the NF2 gene are included. Patients outside Manchester had clinical information and DNA samples sent by geneticists, neurologists, neurosurgeons, and ear, nose, and throat surgeons from throughout the UK and some other European 
RESULTS
The NF2 database consists of 1253 patients (n = 590 [47%] male), mean age at diagnosis was 32.46 yr (range 0.2-82). Two hundred forty-four patients had died with a median age of 39 yr (range 14.4-84.9 yr). There were 1009 patients known to be alive at last follow-up. The median age of this group was 41.3 yr (range 1.0-90.5 yr). All but 85 patients had undergone gene testing, and in 822/1168 (70.4%) a pathogenic NF2 mutations was identified. Six hundred and forty-six were germline (constitutional) mutations with 176 mosaics, while 346 had no identified mutation from blood DNA. Eighty-five patients had not undergone mutation testing. Cause of death was known from the clinical team or from death certification in 175/244 (72%), and no unirradiated patient died from a very rapidly growing VS. There were 1009 patients known to be alive at last follow-up, including 851 UK patients, which is close to the expected prevalence for the whole UK population. 4, 5 The median age of this group was 41.3 yr (range 1.0-90.5 yr).
There were 11 123.1 yr of follow-up from diagnosis in 1148 patients with information on date of diagnosis giving a mean follow-up of 8.92 yr per patient. Follow-up from birth to last follow-up was 51 525.2 yr. In the whole cohort of NF2 patients, 963 NF2 cases had developed bilateral VS (n = 1926 VS) and 188 had a unilateral VS. Thus, 2114 VS had developed in 1151 NF2 patients of which 1150 had been surgically removed. None were reported as MPNST. Ninety-seven patients were yet to develop a VS at a median age of 19 yr. We had no information on VS in 6 patients. One hundred forty-four NF2 patients had received radiation treatment to 185 VS.
There were no cases of spontaneous MPNST. Two patients developed either definite or probable MPNST of the eighth cranial nerve following Gamma Knife radiotherapy (female aged 34, triton tumor 3 yr postradiation) and a presumed case after fractionated radiotherapy (male aged 25, extremely rapidly growing tumor 3 yr postradiation, but no postmortem). There were 3 non-MPNST sarcomas, all in men: an osteosarcoma aged 21 yr, an undifferentiated retroperitoneal sarcoma with epithelioid features aged 23 yr, and an epithelioid sarcoma of the calf aged 52 yr, all in unirradiated individuals. The latter 2 occurred in the last 4 yr and have undergone full review by a sarcoma specialist team.
A single case of malignant melanocytic schwannoma presenting as a unilateral eighth nerve mass, trigeminal mass, and cervical root masses (Figure) who was referred with a possible clinical diagnosis of NF2 was excluded from the series. This man presented at age 54 yr with a foramen magnum lesion that was resected. In follow-up, lesions were found on his cranial nerve and spinal nerve roots. A rapidly growing cervical nerve root was resected and also found to be melanocytic schwannoma. With further imaging, his appearances were consistent with multifocal spread of the malignant tumor along the central nervous system (CNS) to give the appearance of NF2. NF2 mutation testing of his blood and tumor samples showed no involvement of the NF2 gene. He died 4.5 yr after presentation with progressive malignant disease despite chemotherapy and bevacizumab treatment.
DISCUSSION
In the 1253 total cases in the NF2 database, there was only 1 case of proven MPNST with a second probable MPNST, both occurring after radiation treatment. These both occurred 3 yr after stereotactic radiosurgery as reported in the Sheffield series, 6 and a case report. 7 Outside of these cases no spontaneous MPNST occurred in NF2 patients. The excellent review from Carlson et al 2 identified 1 spontaneous sporadic MPNST for every 1000 benign VS from SEER data in North America. Thirty cases of MPNST of the cerebellopontine angle were recorded between 1992 and 2012. The average incidence was 0.017 per 1 million persons per year. In our series, including over 2000 VS, no spontaneous MPNST occurred, which is fewer than the 1 per 1000 expected from the US population data. In reality, the 2114 VS based on laterality represent many more separate primary VS as nearly all VS in NF2 are multifocal. 8 Though there is not sufficient follow-up to have expected an MPNST specifically in the cerebellopontine angle in the 51 525 yr of follow-up from birth in NF2 patients, we also saw no spontaneous MPNST at other sites. The MPNST annual incidence in a UK population was 0.14 per 100 000 from 1983 to 1996, although this dropped to 0.09 per 100 000 if the 36% with neurofibromatosis type 1 (NF1) were excluded. 9 So even accounting for all sites only 0.07 MPNST would have been expected. As such, a much larger series would be required to rule out any increased risk of MPNST in NF2.
The Carlson review 2 identified 2 cases of apparent spontaneous MPNST in NF2 from the published literature. 10, 11 These cases were, however, not definitively NF2 patients. The first referred to multiple neurofibromas of peripheral nerves 10 making NF1 more likely. The second had what appeared to be multifocal MPNST presenting on multiple cranial and peripheral nerve roots. 11 In the absence of a previously confirmed benign schwannoma, this case may just represent multifocal metastatic MPNST. Many types of malignancy including the melanocytic schwannoma in this report have been shown to mimic NF2 including myeloma, melanoma, lymphoma, ependymoma, and lung cancer; [12] [13] [14] [15] [16] [17] [18] another possibility is that this case could actually represent a case of SMARCB1-related schwannomatosis with metastatic MPNST as this association is well established. 19 A further review from 2014 suggested that an additional 3 cases of spontaneous MPNST had occurred in NF2, 3 but these cases should be discounted. One report cited in the review specifically excluded neurofibromatosis, 20 another was of a melanocytic schwannoma 21 that has been shown in the present report to mimic NF2 (melanocytic schwannomas are not a feature of NF2) when it metastasizes in the central nervous system, and a third represented an MPNST occurring in the contralateral side to an apparent sporadic unilateral VS. 22 Both reviews 2, 3 state that there is an increased risk of spontaneous MPNST in unirradiated NF2 patients. The first review identified 30 sporadic MPNSTs of the eighth cranial nerve but none in NF2. As between 4% to 7% of VS affected people have NF2 based on population studies 23 at least 1 to 2 should have been associated with NF2 even if there was no increased risk, yet none occurred. Indeed, as NF2 patients usually develop bilateral VS if there was the same risk of MPNST in each affected eighth nerve then this should have been as high as 2 to 4 cases amongst the 30. The older review 3 set out to calculate a risk of MPNST in cranial nerves in NF2. Given the inaccuracy of the identification of NF2 cases in this review and lack of systematic use gene testing in historical series, it is difficult to confirm the validity of the MPNST rates provided and these should be discounted.
CONCLUSION
There is no evidence that spontaneous MPNST is a feature of NF2. The rate of MPNST per benign VS based on over 2000 VS in NF2 patients is lower than previously reported in the general population. Therefore, based on current evidence, NF2 patients should not be told that they have an increased rate of spontaneous malignant transformation of their VS. Further, larger series of patients with confirmed NF2 are required to provide accurate estimation of any increased risk of spontaneous MPNST or the level of increased risk in those undergoing radiotherapy.
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